Key facts
- Oxolife’s last known valuation is $10K (Jan 2022).
- It has raised $17.1M; the latest was Later Stage VC ($5.7M) in Jun 2025.
- Notable investors include European Innovation Council, INNVIERTE SICC, Inveready Asset Management, BStartup10, Capital Cell — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Oxolife
- ·The full record, as it builds
Funding rounds
No funding rounds for Oxolife are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Oxolife
Operator of a biotechnology company intended to improve female fertility. The company's drug acts directly on the endometrium to enhance embryo implantation and restore ovulation, enabling clinicians to simplify the process that infertile women and couples go through.
- Sector
- Healthcare
- HQ
- Barcelona, Spain
- Founded
- 2013
- Employees
- 10
- Website
- oxolife.com/
- Ownership
- Privately Held (backing)
Oxolife doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Oxolife shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Oxolife in its N-PORT filings yet. We sweep new filings monthly.